Literature DB >> 27100014

Quantification and risks associated with bacterial aerosols near domestic greywater-treatment systems.

Maya Benami1, Allison Busgang1, Osnat Gillor1, Amit Gross2.   

Abstract

Greywater (GW) reuse can alleviate water stress by lowering freshwater consumption. However, GW contains pathogens that may compromise public health. During the GW-treatment process, bioaerosols can be produced and may be hazardous to human health if inhaled, ingested, or come in contact with skin. Using air-particle monitoring, BioSampler®, and settle plates we sampled bioaerosols emitted from recirculating vertical flow constructed wetlands (RVFCW) - a domestic GW-treatment system. An array of pathogens and indicators were monitored using settle plates and by culturing the BioSampler® liquid. Further enumeration of viable pathogens in the BioSampler® liquid utilized a newer method combining the benefits of enrichment with molecular detection (MPN-qPCR). Additionally, quantitative microbial risk assessment (QMRA) was applied to assess risks of infection from a representative skin pathogen, Staphylococcus aureus. According to the settle-plate technique, low amounts (0-9.7×10(4)CFUm(-2)h(-1)) of heterotrophic bacteria, Staphylococcus spp., Pseudomonas spp., Klebsiella pneumoniae, Enterococcus spp., and Escherichia coli were found to aerosolize up to 1m away from the GW systems. At the 5m distance amounts of these bacteria were not statistically different (p>0.05) from background concentrations tested over 50m away from the systems. Using the BioSampler®, no bacteria were detected before enrichment of the GW-aerosols. However, after enrichment, using an MPN-qPCR technique, viable indicators and pathogens were occasionally detected. Consequently, the QMRA results were below the critical disability-adjusted life year (DALY) safety limits, a measure of overall disease burden, for S. aureus under the tested exposure scenarios. Our study suggests that health risks from aerosolizing pathogens near RVFCW GW-treatment systems are likely low. This study also emphasizes the growing need for standardization of bioaerosol-evaluation techniques to provide more accurate quantification of small amounts of viable, aerosolized bacterial pathogens.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Aerosols; Enrichment; Greywater; MPN-qPCR; Pathogens; QMRA

Mesh:

Substances:

Year:  2016        PMID: 27100014     DOI: 10.1016/j.scitotenv.2016.03.200

Source DB:  PubMed          Journal:  Sci Total Environ        ISSN: 0048-9697            Impact factor:   7.963


  5 in total

Review 1.  Quantitative Microbial Risk Assessment and Infectious Disease Transmission Modeling of Waterborne Enteric Pathogens.

Authors:  Andrew F Brouwer; Nina B Masters; Joseph N S Eisenberg
Journal:  Curr Environ Health Rep       Date:  2018-06

2.  Quantitative Microbial Risk Assessment of Antimicrobial Resistant and Susceptible Staphylococcus aureus in Reclaimed Wastewaters.

Authors:  Mary E Schoen; Michael A Jahne; Jay Garland; Lucia Ramirez; Allison J Lopatkin; Kerry A Hamilton
Journal:  Environ Sci Technol       Date:  2021-10-26       Impact factor: 9.028

3.  Optimized Co-extraction and Quantification of DNA From Enteric Pathogens in Surface Water Samples Near Produce Fields in California.

Authors:  Michael B Cooley; Diana Carychao; Lisa Gorski
Journal:  Front Microbiol       Date:  2018-03-13       Impact factor: 5.640

4.  Passive air sampling: the use of the index of microbial air contamination.

Authors:  Isabella Viani; Maria Eugenia Colucci; Massimiliano Pergreffi; Deanna Rossi; Licia Veronesi; Assunta Bizzarro; Emanuela Capobianco; Paola Affanni; Roberta Zoni; Elisa Saccani; Roberto Albertini; Cesira Pasquarella
Journal:  Acta Biomed       Date:  2020-04-10

5.  Microbiological Health Risk Assessment of Water Conservation Strategies: A Case Study in Amsterdam.

Authors:  Agung Kusumawardhana; Ljiljana Zlatanovic; Arne Bosch; Jan Peter van der Hoek
Journal:  Int J Environ Res Public Health       Date:  2021-03-05       Impact factor: 3.390

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.